Rural breast cancer deaths rise faster than urban rates, driven by low income, later diagnosis, and treatment gaps—warning of widening disparities by 2035.
|Videos|December 13, 2019
The monarcHER Trial in Advanced HR+, HER2+ Breast Cancer
Author(s)Sara M. Tolaney, MD, MPH
Sara M. Tolaney, MD, MPH, discusses the results of the monarcHER trial, which examined adding the CDK4/6 inhibitor abemaciclib and endocrine therapy to trastuzumab versus trastuzumab plus chemotherapy in advanced hormone receptor-positive, HER2-positive breast cancer.
Advertisement
Advertisement
Related to this article
Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Selpercatinib Shows Durable Responses in Pediatric Solid Tumors
3
Male Sex, Age, and Tumor Genetics Linked to Thyroid Cancer Mortality
4
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
5